Welcome to our dedicated page for Lifemd news (Ticker: LFMD), a resource for investors and traders seeking the latest updates and insights on Lifemd stock.
LifeMD, Inc. provides virtual primary care through a direct-to-patient telehealth platform that combines telemedicine, laboratory access, pharmacy services, a 50-state affiliated medical group, an affiliated pharmacy and a U.S.-based patient care center. Company news commonly covers its Telehealth operating segment, recurring subscription revenue, patient sign-ups, gross margin trends and guidance.
Recurring updates also address LifeMD’s specialized care areas, including primary care, men’s and women’s health, weight management and hormone therapy. News items feature GLP-1 weight management offerings such as Wegovy and Foundayo, branded therapy access through manufacturer programs, preferred stock dividends, executive leadership changes and investor conference participation.
LifeMD (Nasdaq: LFMD) announced that management will participate in two investor conferences in May 2026: the LD Micro Invitational XVI in Los Angeles and the B. Riley Securities 26th Annual Investor Conference in Marina del Rey, including presentations and one-on-one investor meetings.
LifeMD (NASDAQ: LFMD) reported Q1 2026 revenue of $50.2 million and an adjusted EBITDA loss of $4.5 million, in line with guidance. Gross margin expanded ~420 bps to 88%. Active subscribers rose 26% to ~365,000 with the largest quarterly net adds in company history (~42,000). Cash totaled $34.5 million with no debt. The company affirmed full-year 2026 guidance of $220M–$230M revenue and $12M–$17M adjusted EBITDA, and expects annualized run-rate revenue >$250M by Q4 2026.
LifeMD (Nasdaq: LFMD) will report first quarter 2026 financial results for the period ended March 31, 2026, after market close on May 6, 2026. A conference call and webcast will begin at 4:30 p.m. Eastern that day; dial‑in numbers and a replay will be available.
The event includes a live and archived webcast and standard toll‑free and international dial‑in access for investors and analysts.
LifeMD (Nasdaq: LFMD) announced it is now offering Eli Lilly's oral GLP-1 pill Foundayo (orforglipron) through its weight management program via an integration with LillyDirect. The FDA approved Foundayo on April 1, 2026.
Foundayo is available to eligible patients with a starting self-pay price of $149/month, commercial patients may pay as little as $25/month with a Lilly savings card, and Medicare coverage is anticipated July 2026. LifeMD says the addition expands its branded GLP-1 offerings and supports virtual, clinically guided weight-management services.
LifeMD (Nasdaq: LFMD) launched Novo Nordisk's industry-first Wegovy® (semaglutide) telehealth subscription program on March 31, 2026, expanding its commercial collaboration with Novo Nordisk. Eligible patients can receive structured pricing with up to $1,200 annual savings for injectable Wegovy and $600 for oral therapy.
The program offers end-to-end virtual care across all 50 states, ongoing clinical oversight, nationwide diagnostic testing, and simplified billing, and is available at LifeMD's weight management site.
LifeMD (Nasdaq: LFMD) declared a cash dividend on its 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) of $0.5546875 per share.
The dividend is payable April 15, 2026, to holders of record at the close of business on April 3, 2026.
LifeMD (Nasdaq: LFMD) appointed Atul Kavthekar as Chief Financial Officer, effective March 16, 2026, and announced additional leadership changes to support growth. Marc Benathen will remain through March 31, 2026, to assist transition. LifeMD disclosed an employment inducement of 675,000 restricted stock units for Mr. Kavthekar, split between service- and performance-based vesting.
LifeMD also named Chris Pisano Chief Marketing Officer and promoted Jessica Friedeman to Chief Business Officer; Friedeman joined LifeMD in January 2023.
LifeMD (Nasdaq: LFMD) reported full year 2025 revenue of $194.1 million (up 25%) and adjusted EBITDA of $15.3 million (up 309%). Q4 revenue was $46.9 million (+4%) with adjusted EBITDA of $4.8 million (+348%).
The company exited 2025 with $36.8 million cash, no debt, ~323,000 active subscribers, a benefits infrastructure to cover ~220 million Americans by Q2, and a post‑year‑end launch of oral Wegovy with >80% initiation among new weight management patients.
LifeMD (Nasdaq: LFMD) announced management will participate in two virtual investor conferences in March 2026.
Management will attend the Mizuho Securities Healthcare Technology Conference on March 5 with virtual one-on-one meetings, and the KeyBanc Capital Markets Healthcare Forum March 17-18 with a fireside chat and a panel on March 18.
LifeMD (Nasdaq: LFMD) will report fourth quarter and full-year 2025 financial results after market close on March 9, 2026 and will host a conference call and webcast at 4:30 p.m. Eastern the same day.
Dial-in numbers, conference ID LIFEMD, and a live/archived webcast link will be available for investors.